IMPROVE-PAH is a two-part adaptive Phase 3 program testing IKT-001, an oral prodrug of imatinib, in up to 180 global sites. Part A randomizes roughly 140 patients, with change in pulmonary vascular resistance at Week 24 as the primary endpoint. Part B follows seamlessly with about 346 patients, shifting the primary endpoint to change in 6-minute walk distance at Week 24. The protocol includes a 12-week dose-titration phase to reach each patient’s highest tolerable dose and allows sample-size re-estimation after Part A.
The immediate news is first-patient enrollment, marking the formal start of a single, pivotal global study intended to support an NDA if successful. The company reports written FDA feedback endorsing the adaptive design and the one-pivotal approach. IKT-001 is positioned as a reformulation play: a prodrug designed to mitigate the gastrointestinal side effects that limited the use of imatinib in earlier PAH attempts, while preserving the antiproliferative mechanism targeting PDGFR and related tyrosine kinases.
Strategically, this is a calculated re-entry into a mechanism with prior efficacy signals but a difficult safety and tolerability legacy. The earlier imatinib program in PAH demonstrated improvements in hemodynamics and exercise capacity, yet high discontinuation rates and adverse events prevented regulatory success. Inhibikase is betting that GI-focused tolerability gains via a prodrug, coupled with controlled dose escalation, will unlock the same biology without the attrition. The dual-endpoint structure reflects a hedging strategy: Part A anchors on a hemodynamic readout with cleaner assay sensitivity, while Part B shifts to a functional measure more aligned with how recent therapies have been evaluated. The seamless transition and adaptive features aim to compress timelines and contain risk if effect sizes diverge from assumptions.
For sites, this design brings both opportunity and operational burden. Right-heart catheterization at baseline and Week 24 for PVR will require cardiopulmonary bandwidth and procedural coordination, while 6-minute walk testing demands meticulous standardization across geographies. The 12-week titration phase raises complexity in visit schedules, adherence oversight, and AE management, with a premium on dose-intensity tracking to interpret efficacy. Given imatinib’s historical profile, safety monitoring—particularly for GI events and potential bleeding risks in patients on background anticoagulation—will be central to keeping discontinuations low. CROs will need tight control of data flow, unblinded statistical oversight for adaptive elements, and rapid feedback loops to sites as titration decisions intersect with safety signals. Competing recruitment dynamics in PAH, now reshaped by sotatercept’s entry and expanding background combination therapy, may challenge enrollment and dilute effect sizes unless stratification and concomitant therapy management are rigorously executed.
The forward read-through will come quickly. Part A outcomes will set the tone: magnitude of PVR change, dose intensity achieved by Week 24, discontinuation rates, and the GI and bleeding safety pattern will indicate whether the prodrug thesis holds. Any move to re-estimate Part B’s sample size will be an immediate signal on observed effect and event variance. Regulators will scrutinize not only the primaries but also time to clinical worsening and durability, given the field’s pivot toward composite clinical endpoints and long-term outcomes. Commercial positioning will hinge on whether IKT-001 can layer onto contemporary regimens without unacceptable toxicity and whether the operational complexity of titration is offset by clinically meaningful gains. Watch for pace of site activations, geographic enrollment balance, and protocol amendments around background therapy and safety management—early indicators of whether this single-pivotal strategy can survive contact with real-world PAH trial execution.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
